Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05411718 · ClinicalTrials.gov registry record · Phase 2

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

A Phase 2 study of Colorectal Cancer and Lynch Syndrome, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT05411718: Recruiting Phase 2 study of Colorectal Cancer and Lynch Syndrome, sponsored by M.D. Anderson Cancer Center.

NCT05411718 is a Phase 2 study of Colorectal Cancer and Lynch Syndrome that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05411718, a Phase 2 study of Colorectal Cancer and Lynch Syndrome, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.

Conditions Studied

Colorectal Cancer Lynch Syndrome T Cells

Interventions

  • DRUG Aspirin
  • DRUG Naproxen

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-03-21
Est. Completion 2026-11-30
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT05411718 shows while recruiting

NCT05411718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.

NCT05411718 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05411718 about?

NCT05411718 is a clinical study titled "A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome". To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.

What is the current status of trial NCT05411718?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-03-21. Estimated completion is 2026-11-30.

What conditions does trial NCT05411718 study?

This clinical trial studies the following conditions: Colorectal Cancer, Lynch Syndrome, T Cells.

What interventions are being tested in trial NCT05411718?

The interventions under investigation include: Aspirin (DRUG), Naproxen (DRUG).

Who is sponsoring clinical trial NCT05411718?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05411718 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05411718's enrollment target sits among peer trials

40 298th of 381 higher than 76 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05411718

Source: ClinicalTrials.gov NCT05411718, the US trial registry maintained by the National Library of Medicine. NCT05411718 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.